A report on notable recent FDA safety label changes: contrast agents used in MRIs, eczema drug Dupixent, cancer drug Keytruda, diabetes drug Rybelsus, and bipolar drug Lybalvi.
Drug Safety Label Updates: February 2024
A report on notable recent FDA safety label changes: contrast agents used in MRIs, eczema drug Dupixent, cancer drug Keytruda, diabetes drug Rybelsus, and bipolar drug Lybalvi.